Clinical trials: Glomerular Filtration Rate
Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate From Digital Retinal Images
Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate
This is a non-interventional pilot study with the following objectives: Establish scalable methodology for collection of retinal images, blood pressure (BP) and laboratory-based assessments Compare the results of a…
- Trial name
- NCT04814680
- Where
- 2 sites in Kenya
- Volunteers
- 301 people
- Sponsor
- AstraZeneca
Healthy Volunteers
Effect of Fenofibrate on Kidney Function: a Six-week Randomized Cross-over Trial in Healthy People
The purpose of this study was to test the effect of fenofibrate treatment on glomerular filtration rate (GFR), kidney hemodynamics and tubular function in middle-aged subjects with normal kidney function to further investigate…
- Trial name
- NCT00543647
- Testing
- Fenofibrate 160 mg tablet
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Chronic Kidney Disease, Type 2 Diabetes
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
This is a 24-week multi-center, double-blind, randomized, exploratory study of bardoxolone methyl treatment in 18 patients with Stage 3 CKD (eGFR greater than or equal to 30.0 to less than 60.0 ml/min/1.73m2) and diabetes to…
- Trial name
- NCT01500798
- Testing
- 20 mg bardoxolone methyl
- Volunteers
- 18 people
- Sponsor
- Biogen
Healthy
Comparison of Extended Release Tacrolimus (Advagraf) and Cyclosporine A Microemulsion on Renal Function in Healthy Volunteers
The purpose of this study is to compare the effects of steady state tacrolimus vs. cyclosporine on renal pharmacodynamics in healthy volunteers.
- Trial name
- NCT00818194
- Testing
- extended release tacrolimus, cyclosporine A microemulsion
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Lupus Nephritis
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
This was a pivotal, randomized, double-blind, placebo-controlled trial evaluating at Week 52 the efficacy and safety of secukinumab versus placebo in patients with active lupus nephritis (ISN/RPS Class III or IV, with or without…
- Trial name
- SELUNE (NCT04181762)
- Testing
- secukinumab
- Where
- 105 sites in United States, Argentina and 32 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Renal Insufficiency, Diabete Mellitus
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus…
- Conditions
- Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure
- Trial name
- NCT01252810
- Testing
- GE-145
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- GE Healthcare
Renal Function
Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data
Scientific analyses are frequently performed on e.g. health insurance databases to study the usage and effectiveness of drugs in real life.
- Trial name
- NCT03605810
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 5,132,200 people
- Sponsor
- Bayer
Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.
To assess the safety, tolerability and pharmacokinetics of ABT-614 in subjects with type 2 diabetes and chronic kidney disease with albuminuria and to determine whether ABT-614 reduces glomerular filtration rate.
- Trial name
- NCT01464320
- Testing
- ABT-614
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Abbott
Lupus Nephritis
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
The purpose of this study was to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).
- Trial name
- NCT05781750
- Testing
- zetomipzomib
- Where
- 50 sites in United States, Argentina and 10 more
- Volunteers
- 84 people
- Sponsor
- Kezar Life Sciences, Inc.
Kidney Transplantation
Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients
This study will investigate the safety, tolerability and efficacy of EC-MPS with tacrolimus at both reference and reduced levels.
- Trial name
- NCT00229138
- Testing
- EC-MPS, Tacrolimus
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Novartis Pharmaceuticals
Renal Impairment, Heart Failure
A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment
A study to investigate the effects and safety of AZD5462 on top of dapagliflozin in participants with heart failure and moderate renal impairment.
- Trial name
- AURORA (NCT06639087)
- Testing
- AZD5462, Dapagliflozin
- Where
- Bulgaria
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Renal Tolerance, Digestive Tolerance
Renal and Digestive Tolerance of a Food Supplement, Phytalgic, in Elderly Volunteers - A Multicentric Open Trial
The aim of the study is to evaluate renal and digestive tolerance of a food supplement, phytalgic, on elderly volunteers.
- Trial name
- NCT01203670
- Testing
- Phytalgic
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Phythea
Glomerular Filtration Rate, Acute Kidney Injury
Pharmacokinetics of MP-3180 in Healthy Volunteers
The purpose of this study was to investigate the pharmacokinetics of MP-3180 (1 µmol/kg) compared to the pharmacokinetics of iohexol (5 mL of a 300 mg iodine (I)/mL solution) in healthy adult participants.
- Trial name
- Pilot 1A (NCT02098174)
- Testing
- MP-3180, Iohexol comparator
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- MediBeacon
C3 Glomerulopathy, Complement-mediated Kidney Disease
CHART-C3G/CLNP023B12011
This is a non-interventional chart abstraction cohort study with longitudinal follow up. Patients with C3G treated with iptacopan will be enrolled and characterized (i.e., systematically describe and summarize) regarding their…
- Conditions
- C3 Glomerulopathy, Complement-mediated Kidney Disease, Proteinuria
- Trial name
- NCT07331259
- Testing
- Iptacopan
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of…
- Trial name
- NCT02229214
- Testing
- Qsymia
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Chronic Kidney Disease
Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
The goal of this clinical trial was to compare transdermal glomerular filtration rate (tGFR) to plasma-derived indexed (to body surface area; BSA) GFR (nGFR) using MB-102 (relmapirazin) as the fluorescent compound.
- Trial name
- NCT05425719
- Testing
- MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- Where
- 8 sites in United States, China
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Lupus Nephritis
Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
The purpose of this open-label extension study was to provide treatment with secukinumab for subjects who completed core study treatment in Study CAIN457Q12301 (NCT04181762), and to obtain further data on long-term efficacy…
- Trial name
- NCT05232864
- Testing
- Secukinumab
- Where
- 18 sites in Australia, Brazil and 11 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Diseases, Kidney Injury
Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
The goal of this clinical trial was to compare transdermal glomerular filtration rate (tGFR) to plasma-derived indexed GFR (nGFR) using MB-102 (relmapirazin) as the fluorescent compound.
- Conditions
- Kidney Diseases, Kidney Injury, Kidney Failure
- Trial name
- NCT05777174
- Testing
- MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- Where
- 5 sites in United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Fabry Disease
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
The objective of CLI-06657AA1-03 (formerly PB-102-F51) is to evaluate the long-term safety, tolerability, and efficacy of 2 mg/kg pegunigalsidase alfa administered intravenously every four weeks in adult Fabry patients who have…
- Trial name
- NCT03614234
- Testing
- pegunigalsidase alfa
- Where
- 14 sites in United States, Belgium and 5 more
- Volunteers
- 29 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Type 2 Diabetes Mellitus, Cardiovascular Disease
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)
The purpose of this study was to determine whether, in patients with type 2 diabetes and pre-existing disease of the heart and the circulatory system and/or the kidney, aliskiren at a target dose of 300 mg once daily (compared to…
- Trial name
- ALTITUDE (NCT00549757)
- Testing
- Aliskiren
- Where
- 776 sites in United States, Argentina and 35 more
- Volunteers
- 8,606 people
- Sponsor
- Novartis Pharmaceuticals